BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 7288624)

  • 1. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
    Abuchowski A; Karp D; Davis FF
    J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
    Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypouricaemic effect after oral administration in chickens of polyethylene glycol-modified uricase entrapped in liposomes.
    Nishida Y; Kamatani N; Miyamoto T
    J Pharm Pharmacol; 1984 May; 36(5):354-5. PubMed ID: 6145782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.
    Chua CC; Greenberg ML; Viau AT; Nucci M; Brenckman WD; Hershfield MS
    Ann Intern Med; 1988 Jul; 109(2):114-7. PubMed ID: 3289428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers.
    Caliceti P; Schiavon O; Veronese FM
    Bioconjug Chem; 1999; 10(4):638-46. PubMed ID: 10411462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A micromethod for plasma uric acid determinations in companion birds.
    McFarland DC; Kenzy SG; Coon CN
    Avian Dis; 1979; 23(3):772-4. PubMed ID: 526210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of yeast uricase with polyethylene glycol: disappearance of binding ability towards anti-uricase serum.
    Nishimura H; Ashihara Y; Matsushima A; Inada Y
    Enzyme; 1979; 24(4):261-4. PubMed ID: 573687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the uricase-inhibited rat as an animal model in toxicology.
    Stavric B; Nera EA
    Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigations into the uricolytic properties of urate oxidase in a granivorous (Columba livia domestica) and in a carnivorous (Buteo jamaicensis) avian species.
    Poffers J; Lumeij JT; Redig PT
    Avian Pathol; 2002 Dec; 31(6):573-9. PubMed ID: 12593740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.
    Tan QY; Zhang JQ; Wang N; Yang H; Li X; Xiong HR; Wu JY; Zhao CJ; Wang H; Yin HF
    Int J Nanomedicine; 2012; 7():3929-38. PubMed ID: 22915844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of a thermostable uricase by a novel Bacillus thermocatenulatus strain.
    Lotfy WA
    Bioresour Technol; 2008 Mar; 99(4):699-702. PubMed ID: 17395458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity.
    Nishimura H; Matsushima A; Inada Y
    Enzyme; 1981; 26(1):49-53. PubMed ID: 7194181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved performance of polyaniline-uricase biosensor.
    Arora K; Sumana G; Saxena V; Gupta RK; Gupta SK; Yakhmi JV; Pandey MK; Chand S; Malhotra BD
    Anal Chim Acta; 2007 Jun; 594(1):17-23. PubMed ID: 17560380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cloning and expression of urate oxidase and its application in serum uric acid analysis].
    Zhu XJ; Liu JG; Li GX
    Sheng Wu Gong Cheng Xue Bao; 2001 Jan; 17(1):68-72. PubMed ID: 11330191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase.
    Tsuji J; Hirose K; Kasahara E; Naitoh M; Yamamoto I
    Int J Immunopharmacol; 1985; 7(5):725-30. PubMed ID: 2412977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.